No. of Patients/ Metastases | Perent | Median | Minimum | Maximum | |
---|---|---|---|---|---|
474 pts. | |||||
Age (yr) | 64 | 15 | 93 | ||
Sex | |||||
male | 268 pts. | 56.7% | |||
female | 206 pts. | 43.3% | |||
Pretreatment performance scale (Karnofsky index) (%) | 90 | 40 | 100 | ||
Histology | |||||
Colorectal cancer | 228 pts. | 48.1% | |||
Breast cancer | 63 pts. | 13.3% | |||
NSCLC | 29 pts. | 6.1% | |||
Pancreatic cancer | 24 pts. | 5.1% | |||
Others | 130 pts. | 27.4% | |||
Chemotherapy prior to SBRT | |||||
Yes | 325 pts. | 65.6% | |||
No | 80 pts. | 16.9% | |||
Unknown | 68 pts. | 17.6% | |||
Number of liver metastases per patient | 474 pts. / 623 mets | 1 | 1 | 4 | |
n = 1 | 372 pts. | 78.5% | |||
n = 2–4 | 102 pts. | 21.5% | |||
Status of extrahepatic disease | |||||
Oligo-recurrence group | 119 pts. | 25.1% | |||
Sync-oligometastases group | 235 pts. | 49.6% | |||
Unknown | 120 pts. | 25.3% | |||
Time interval between primary tumor diagnosis and SBRT treatment (months) | 27.0 | 0.0 | 391.0 | ||
Follow-up (months) | 15 | 1 | 178 |